Efficacy and safety of Omalizumab in the treatment of Chronic Urticarial; a case series.
DOI:
https://doi.org/10.66344/jpad.v27i3.1058Keywords:
Omalizumab, Urticaria, IgE.Abstract
Chronic Idiopathic Urticaria (CIU) is a disease with significant impact on the quality of life owing to its morbidity and relative prevalence. Omalizumab is a recombinant monoclonal antibody against IgE that inhibits the binding of IgE to FcεRI on the cell surface. Its role has been thoroughly studied in asthma.
We present case series focusing on the role of subcutaneous Omalizumab in the treatment of CIU along with its safety profile by taking into account the immediate and late side effects.
References
1. Greaves MW. Chronic urticaria. N Engl J Med. 1995;332:1767-72. [Erratum, N Engl J Med. 1995;333:1091.]
2. Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol. 2008;20:709-16.
3. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151:2623-32.
4. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164:S6-11.
5. Owen CE. Anti-immunoglobulin E therapy for asthma. Pulm Pharmacol Ther. 2002;15:417-24.
6. Reich A, Medrek K, Szepietowski JC. Four-item itch questionnaire – validation of questionnaire. Przegl Dermatol. 2012;99: 600-4.
7. Naaman S, Sussman G. Chronic idiopathic urticaria: treatment with omalizumab. Skin Therapy Lett. 2014;19(6):1-4.
8. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector S, Maurer M: A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567-73.e1.
9. Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-35.
10. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-35.
11. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157-62.
12. Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: A randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67-75.
13. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438-45.
14. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J Allergy Clin Immunol. 2004;114:527-30.
15. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112:1147-54.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Asif Kamal, Maryum Nouman
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
